Biomarin Competitors
| BMRN Stock | USD 59.87 0.07 0.12% |
Biomarin Pharmaceutical vs Qiagen NV Correlation
Weak diversification
The correlation between Biomarin Pharmaceutical and QGEN is 0.31 (i.e., Weak diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Biomarin Pharmaceutical and QGEN in the same portfolio, assuming nothing else is changed.
Moving together with Biomarin Stock
Moving against Biomarin Stock
| 0.6 | DRMA | Dermata Therapeutics | PairCorr |
| 0.45 | VANI | Vivani Medical | PairCorr |
| 0.36 | RAC | Race Oncology Earnings Call This Week | PairCorr |
| 0.31 | OB3 | OPTIBIOTIX HLTH PLC | PairCorr |
Biomarin Pharmaceutical Competition Correlation Matrix
Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Biomarin Pharmaceutical and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Biomarin and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Biomarin Pharmaceutical does not affect the price movement of the other competitor.
High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Biomarin Stock performing well and Biomarin Pharmaceutical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Biomarin Pharmaceutical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.| Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
|---|---|---|---|---|---|---|---|---|---|---|
| EXEL | 1.57 | 0.05 | 0.02 | 0.13 | 1.75 | 3.79 | 10.16 | |||
| MRNA | 3.45 | 0.79 | 0.21 | 0.43 | 3.66 | 9.21 | 23.11 | |||
| RVMD | 2.31 | 0.74 | 0.19 | 54.88 | 2.98 | 4.56 | 45.50 | |||
| TECH | 1.84 | (0.01) | 0.01 | 0.05 | 1.99 | 3.74 | 12.41 | |||
| HALO | 1.66 | 0.20 | 0.09 | 0.32 | 1.78 | 3.72 | 9.83 | |||
| MDGL | 1.91 | (0.12) | 0.00 | (0.08) | 0.00 | 4.57 | 16.78 | |||
| RNA | 0.17 | 0.05 | (0.03) | 0.51 | 0.00 | 0.38 | 1.75 | |||
| BBIO | 1.95 | 0.24 | 0.07 | 0.26 | 3.10 | 5.40 | 21.24 | |||
| ALGN | 1.74 | 0.38 | 0.21 | 0.29 | 1.60 | 4.70 | 15.79 | |||
| QGEN | 1.34 | 0.36 | 0.25 | (0.77) | 0.86 | 2.86 | 19.34 |
Cross Equities Net Income Analysis
Compare Biomarin Pharmaceutical and related stocks such as Exelixis, Moderna, and Revolution Medicines Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| EXEL | (15.7 M) | 75.7 M | (147.6 M) | (244.8 M) | (268.5 M) | (169.7 M) | (70.2 M) | 154.2 M | 690.1 M | 321 M | 111.8 M | 231.1 M | 182.3 M | 207.8 M | 521.3 M | 782.6 M | 821.7 M |
| MRNA | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (6.5 M) | (1.1 M) | (216.2 M) | (255.9 M) | (384.7 M) | (514 M) | (747.1 M) | 12.2 B | 8.4 B | (4.7 B) | (3.6 B) | (2.8 B) | (2.7 B) |
| RVMD | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (31.1 M) | (41.8 M) | (47.7 M) | (108.2 M) | (187.1 M) | (248.7 M) | (436.4 M) | (600.1 M) | (540.1 M) | (513.1 M) |
| TECH | 400 K | 112.3 M | 112.6 M | 110.9 M | 107.7 M | 104.5 M | 77.3 M | 125.3 M | 96.1 M | 229.3 M | 140.4 M | 272.1 M | 285.3 M | 168.1 M | 73.4 M | 84.4 M | 87.1 M |
| HALO | (39.7 K) | (19.8 M) | (53.6 M) | (83.5 M) | (68.4 M) | (32.2 M) | (103 M) | 63 M | (80.3 M) | (72.2 M) | 129.1 M | 402.7 M | 202.1 M | 281.6 M | 444.1 M | 510.7 M | 536.2 M |
| MDGL | (381 K) | (47.4 M) | (62.8 M) | (90.2 M) | (86.2 M) | (6.8 M) | (26.4 M) | (31.2 M) | (32.8 M) | (72.8 M) | (197.4 M) | (241.1 M) | (295.4 M) | (373.6 M) | (465.9 M) | (419.3 M) | (398.3 M) |
| RNA | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (24.7 M) | (44 M) | (117.4 M) | (169.1 M) | (212.2 M) | (322.3 M) | (290.1 M) | (275.6 M) |
| BBIO | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (30.6 M) | (130.7 M) | (260.4 M) | (448.7 M) | (562.5 M) | (481.2 M) | (643.2 M) | (535.8 M) | (482.2 M) | (506.3 M) |
| ALGN | (15.4 M) | 66.7 M | 58.7 M | 64.3 M | 145.8 M | 144 M | 189.7 M | 231.4 M | 400.2 M | 442.8 M | 1.8 B | 772 M | 361.6 M | 445.1 M | 421.4 M | 410.4 M | 234 M |
| QGEN | 2.4 M | 96 M | 129.5 M | 69.1 M | 116.4 M | 130.1 M | 80.4 M | 40.4 M | 190.4 M | (41.5 M) | 359.2 M | 512.6 M | 423.2 M | 341.3 M | 83.6 M | 424.9 M | 446.1 M |
Biomarin Pharmaceutical and related stocks such as Exelixis, Moderna, and Revolution Medicines Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Biomarin Pharmaceutical financial statement analysis. It represents the amount of money remaining after all of Biomarin Pharmaceutical operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.Biomarin Pharmaceutical Competitive Analysis
The better you understand Biomarin Pharmaceutical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Biomarin Pharmaceutical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Biomarin Pharmaceutical's competition over several years is one of the best ways to analyze its investment potential.| Better Than Average | Worse Than Peers | View Performance Chart |
Biomarin Pharmaceutical Competition Performance Charts
Five steps to successful analysis of Biomarin Pharmaceutical Competition
Biomarin Pharmaceutical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Biomarin Pharmaceutical in relation to its competition. Biomarin Pharmaceutical's competition analysis typically involves several steps, including:- Identifying the key players in the market: This involves identifying the major competitors of Biomarin Pharmaceutical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
- Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
- Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Biomarin Pharmaceutical's competitive landscape.
- Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Biomarin Pharmaceutical, and developing a strategy to address them.
- Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Complement your Biomarin Pharmaceutical position
In addition to having Biomarin Pharmaceutical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Gold and Gold Mining Thematic Idea Now
Gold and Gold Mining
Large and mid-size companies, ETFs and funds that are either investing, exploring or producing, gold or indirectly involved in trading or making gold products. The Gold and Gold Mining theme has 100 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Gold and Gold Mining Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Biomarin Pharmaceutical Correlation with its peers. To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Will Biotechnology sector continue expanding? Could Biomarin diversify its offerings? Factors like these will boost the valuation of Biomarin Pharmaceutical. Projected growth potential of Biomarin fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Biomarin Pharmaceutical data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth 1.243 | Earnings Share 2.69 | Revenue Per Share | Quarterly Revenue Growth 0.041 | Return On Assets |
Understanding Biomarin Pharmaceutical requires distinguishing between market price and book value, where the latter reflects Biomarin's accounting equity. The concept of intrinsic value - what Biomarin Pharmaceutical's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. Market sentiment, economic cycles, and investor behavior can push Biomarin Pharmaceutical's price substantially above or below its fundamental value.
It's important to distinguish between Biomarin Pharmaceutical's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Biomarin Pharmaceutical should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, Biomarin Pharmaceutical's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.